drugset / Trial / NCT00578734

Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old

NCT00578734

Phase 2 Completed 165 enrolled Windtree Therapeutics
RandomizedParallel-groupTriple-blindTreatment

Summary

Treatment with lucinactant, a peptide-containing synthetic lung surfactant, will be evaluated in young children with acute respiratory failure who require mechanical ventilation (life support), to determine if it is safe and if treatment with lucinactant will reduce the number of days a child needs mechanical ventilation (life support).

Timeline

Start
2007-06
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Lucinactant Peptide 175 mg/kg Other